EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation

Steffi Verbeeck Mendez iD, Isabella L Do Orozco, Guadalupe E Gavilanez-Chavez, Arnulfo Hernán Nava-Zavala iD, Maria G Zavala-Cerna iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26083850 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Steffi Verbeeck Mendez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina, Universidad Autónoma de Guadalajara, Guadalajara 45129, Mexico. Hauptthemen laut MEDLINE: COVID-19, Immunomodulation, Immunomodulating Agents, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UAG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The resolution of the recent COVID-19 pandemic still requires attention, since the consequences of having suffered the infection, even in mild cases, are associated with several acute and chronic pathological conditions referred to as post-COVID syndrome (PCS). PCS often manifests with pulmonary disease and, in up to 9% of cases, a more serious complication known as post-COVID-19 pulmonary fibrosis (PC19-PF), which has a similar clinical course as idiopathic pulmonary fibrosis (IPF). Generating knowledge to provide robust evidence about the clinical benefits of different therapeutic strategies to treat the pulmonary effects of PCS can provide new insights to amplify therapeutic options for these patients. We present evidence found after a scoping review, following extended PRIMSA guidelines, for the use of immunomodulators in pulmonary PCS. We start with a brief description of the immunomodulatory properties of the relevant drugs, their clinically proven efficacy for viral infections and chronic inflammatory conditions, and their use during the COVID-19 pandemic. We emphasize the need for well-designed clinical trials to improve our understanding the physiopathology of pulmonary PCS and PC19-PF and also to determine the efficacy and safety of candidate treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19ImmunomodulationImmunomodulating AgentsImmunologic FactorsPulmonary FibrosisHumansSARS-CoV-2COVID-19 Drug TreatmentIdiopathic Pulmonary Fibrosis

Stichwörter der Autor:innen

coronavirus infectionimmunomodulationpost-COVID syndromepost-COVID-19 pulmonary fibrosis

Substanzen

Immunomodulating AgentsImmunologic Factors

Autor:innen und Institutionen

  • Facultad de Medicina, Universidad Autónoma de Guadalajara, Guadalajara 45129, Mexico.
  • Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Hospital General Regional 46, Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Mexico.
  • Unidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Mex…
  • Programa Internacional de Medicina, Universidad Autónoma de Guadalajara, Guadalajara 45129, Mexico.
  • Departamento de Inmunología y Reumatología, Hospital General de Occidente, Secretaría de Salud Jalisco, Zapopan 45170, Mexico.

ORCID-Profile: Steffi Verbeeck Mendez, Arnulfo Hernán Nava-Zavala, Maria G Zavala-Cerna

Förderung

  • UAG

Zitieren

APA

Verbeeck Mendez, S., Do Orozco, I. L., Gavilanez-Chavez, G. E., Nava-Zavala, A. H., & Zavala-Cerna, M. G. (2025). Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083850

Vancouver

Verbeeck Mendez S, Do Orozco IL, Gavilanez-Chavez GE, Nava-Zavala AH, Zavala-Cerna MG. Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083850

BibTeX
@article{VerbeeckMendez2025,
  author = {Verbeeck Mendez, Steffi and Do Orozco, Isabella L and Gavilanez-Chavez, Guadalupe E and Nava-Zavala, Arnulfo Hernán and Zavala-Cerna, Maria G},
  title = {Challenges and Opportunities for Post-COVID Pulmonary Disease: A Focused Review of Immunomodulation},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26083850}
}
Kostenlos starten →